1 Patients received 1 of 2 low-intensity computerised CBT
2 Patients received 1 or more everolimus-eluting stent imp
3 Patients received 1 year of adjuvant sunitinib (50 mg),
4 Twenty-two
patients received 1.8 mg/kg BV and 375 mg/m(2) DTIC for
5 g/m(2) DTIC for up to 12 cycles, and 20 more
patients received 1.8 mg/kg BV plus 90 or 70 mg/m(2) ben
6 Of 95 included patients, 47
patients received 150 mg losartan daily (age, 38.0+/-12.
7 tients (mean age, 57 years; women, 43%), 156
patients received 1or more dose(s) of study medication,
8 Patients received 2 single 150-MBq intravenous injection
9 In addition, 20
patients received 20 mg of furosemide before late scans.
10 Patients received 28-day treatment cycles; the primary o
11 Each
patient received 3 doses of the quadrivalent HPV vaccine
12 In the dose-escalation phase,
patients received 3 to 80 mg/m(2) of selinexor in 3- or
13 Eleven
patients received 325 +/- 29 (mean +/- SD) MBq of the cy
14 Once in complete remission,
patients received 4 cycles of ATRA plus ATO consolidatio
15 The remaining
patients received 4 mg/d.
16 The
patients received 4 or 6 consecutive cycles of R-CHOP de
17 FMT-randomized
patients received 5 days of broad-spectrum antibiotic pr
18 After a 5-day washout period, five
patients received 5 mg apixaban twice daily for 8 days.
19 Patients received 5 mg/kg belatacept every 2 weeks, and
20 In a separate session,
patients received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi
21 Patients received 500 mg intravenous REP 2139 once per w
22 After enrolment,
patients received 6 weeks of medication optimisation.
23 After a minimum 4-h fast,
patients received 740 MBq/1.7 m(2) (maximum, 740 MBq [20
24 All consecutive
patients received 75 mg intravenously once per week.
25 Patients received 750 mg of intravenous mepolizumab or p
26 Patients received (
89)Zr-bevacizumab (0.1 mg/kg; 0.9 MBq
27 A 57-year-old male
patient received a liver transplant for alcoholic cirrho
28 All
patients received a 3-year NA treatment and 1 year off-t
29 er a median follow-up of 1.5 years, 11.6% of
patients received a colon cancer screening test (57.9 te
30 Patients and Methods One hundred thirty-four
patients received a combination of lenalidomide, bortezo
31 At both visits,
patients received a complete ophthalmologic evaluation t
32 Results A total of 86
patients received a diagnosis of babesiosis during the 7
33 Whereas 1975
patients received a KT and were censored, 1876 were on t
34 Three of the
patients received a low dose (6.7x10(13) vg per kilogram
35 Patients and Methods
Patients received a lymphodepleting preparative regimen,
36 Patients received a median (range) of 8 (1-15) cycles of
37 Patients received a median cumulative activity of 14.8 G
38 Patients received a median of 5 prior therapies (range,
39 Patients received a median of two (IQR 1-2) previous the
40 Patients received a melphalan-based reduced-intensity co
41 Patients received a minimum of 180 days of double-blind
42 Most
patients received a myeloablative conditioning regimen (
43 Patients received a postal questionnaire asking for cont
44 ad undergone EDT and 81.9% (n = 59) of these
patients received a probable molecular diagnosis.
45 assess eQMs about classification of whether
patients received a process, we calculated the proportio
46 Fifty-five (96.5%)
patients received a regimen that included the use of nuc
47 Patients received a single 150-MBq intravenous injection
48 Patients received a single dose of CAR-19 T cells 2 days
49 In a 3 + 3 dose-escalation design (n = 25),
patients received a single dose of varlilumab (0.1, 0.3,
50 MDD
patients received a single infusion of ketamine and unde
51 All
patients received a standard clinical evaluation, includ
52 Patients received a standardised cervical injection of i
53 Patients received a subretinal injection of rAAV2-CB-hRP
54 All
patients received a systematic screening using serial me
55 Patients received a target dose of 2x10(6) anti-CD19 CAR
56 In the experimental arm, ePET-negative
patients received ABVD only (noninferiority design), whe
57 eceived TCH (1,444 PP; 848 no PP); and 1,638
patients received AC (857 PP; 781 no PP) regimen.
58 y a 1-year open-label phase during which all
patients received active treatment with opicapone.
59 pare the risk of MVCs during months in which
patients received ADHD medication with the risk of MVCs
60 Approximately 59% of surgical
patients received adjuvant CRT.
61 67% of
patients received adrenaline, 85% oral antihistamines, a
62 110 (72%) of 153
patients received all four pembrolizumab plus ipilimumab
63 All
patients received all-trans retinoic acid (ATRA) during
64 A total of 660 patients were included; 197
patients received alvimopan and 463 patients had no alvi
65 urvival) and the individual hospital where a
patient received an operation.
66 Forty-six percent of
patients received an antibiotic prescription; most presc
67 fter a 4- to 6-month integration period, all
patients received an implant-supported fixed prostheses.
68 Patients received an intravenous infusion of 7.5 mg/kg M
69 Twenty-four
patients received androgen-deprivation therapy (ADT) and
70 All
patients received anti-HCV treatment before or after inc
71 ose, subcutaneous), whereas 35 nonsensitized
patients received anti-IL-2R.
72 cohort was 4.6% (25/544); 94.9% (516/544) of
patients received antibiotics on day 0, and 1.1% (6/544)
73 Approximately 44% of
patients received antineoplastic agents in the last 30 d
74 ion and graft-versus-host disease (GVHD); no
patient received any posttransplantation GVHD prophylaxi
75 Seven
patients received apixaban 2.5 mg twice daily for 8 days
76 343 (78%)
patients received appropriate therapy compared with 94 (
77 Results Overall, 21.9% of
patients received aRT.
78 8.4%) patients received DAPT and 251 (31.6%)
patients received aspirin alone.
79 35 days ("fresh" blood), whereas 429 (31.4%)
patients received at least 1 unit of PRBC that had been
80 Between Jan 22, 2014, and July 10, 2015, 54
patients received at least one dose of lorlatinib, inclu
81 103
patients received at least one dose of lumacaftor and iv
82 All enrolled
patients received at least one dose of pembrolizumab and
83 8, 2016, 374 patients were enrolled and 370
patients received at least one dose of pembrolizumab.
84 one dose of lumacaftor and ivacaftor and 101
patients received at least one dose of placebo.
85 All enrolled
patients received at least one dose of study drugs.
86 362
patients received at least one dose of study medication
87 A total of 811
patients received at least one dose of study treatment.
88 atients) or chemotherapy (134 patients), 376
patients received at least one dose.
89 For induction, all
patients received ATRA (45 mg/m(2) daily) and ATO (0.15
90 transplantation (ASCT) whereas PET-positive
patients received augICE before ASCT.
91 Patients received BAT, which consisted of intramuscular
92 All
patients received bilateral intraputaminal injections of
93 Most
patients received bioprosthetic valves (AVR+ARE: 73.4% v
94 All
patients received both treatments.
95 omprehensive public health initiatives, more
patients received bystander CPR and first-responder defi
96 Enrolled
patients received capecitabine (825 mg/m(2) orally twice
97 Fibrillation), we determined how frequently
patients received care that was concordant with 11 recom
98 sults In all, 188 patients were enrolled; 94
patients received CE and 94 patients received PaCE.
99 Studies were eligible if
patients received chemoradiotherapy or radiotherapy as t
100 Twenty-nine
patients received chemotherapy (including bortezomib in
101 Approximately, 40.1% (94,980) of
patients received chemotherapy: 87% (82,588) aCT and 13.
102 e or paclitaxel and gemcitabine; nonsquamous
patients received cisplatin and pemetrexed or paclitaxel
103 Patients received complete preoperative and postoperativ
104 Oncology clinical trial RTOG 0617, in which
patients received concurrent chemotherapy of carboplatin
105 Medically fit
patients received concurrent weekly carboplatin plus pac
106 The first
patient received continuous veno-venous hemofiltration.
107 Patients received continuous oral ibrutinib (560 mg) dai
108 All
patients received continuous veno-venous hemodialysis du
109 Among T2MI2007, 6.3% of
patients received coronary revascularization, 22% dual-a
110 Nine
patients received corticosteroid therapy.
111 Twenty of 24
patients received cyclophosphamide and fludarabine lymph
112 All
patients received cyclophosphamide or rituximab.
113 At 30 days post-CABG, 544 (68.4%)
patients received DAPT and 251 (31.6%) patients received
114 Patients received daratumumab 16 mg/kg at the recommende
115 Of 3167 patients, 1163 (37%)
patients received definitive therapy with cefazolin.
116 n April 2003 and December 2010; 2400 and 845
patients received DES and BMS, respectively.
117 The
patient received different antiviral therapy regimens (p
118 All
patients received docetaxel 75 mg/m(2) intravenously wit
119 Every 4 weeks, randomized
patients received dosing with placebo or 75, 150, or 300
120 All
patients received doxorubicin (Adriamycin), bleomycin, v
121 ebo-controlled OmegAD study, in which 174 AD
patients received either 1.7 g DHA and 0.6 g EPA (the n-
122 Patients received either ATLG or placebo 20 mg/kg per da
123 Patients received either INCS daily (fluticasone propion
124 3666), 6.3% (n = 3534), and 8.3% (n = 4628)
patients received either interferon-based dual, triple,
125 ebo over 15 days; in a fourth biopsy cohort,
patients received either Nexvax2 at the maximum tolerate
126 Patients received either subcutaneous IFN-alpha2a, syste
127 Patients received either turning care relying on traditi
128 All
patients received elbasvir (EBR) 50 mg/grazoprevir (GZR)
129 In part 1, 17
patients received eltrombopag and 11 patients completed
130 During part 1,
patients received eltrombopag, and dose-escalation crite
131 Patients received endoxifen once daily at seven dose lev
132 Patients received eravacycline, 1.0 mg/kg every 12 hours
133 Beginning on day 1 of cycle 1,
patients received everolimus 10 mg plus exemestane 25 mg
134 Patients received EVL (target trough level (Ctrough, 3-8
135 l-lowering therapy for at least 4 weeks; all
patients received evolocumab 420 mg subcutaneously month
136 Two thousand three hundred ninety-eight
patients received exclusively balanced fluids at 24 hour
137 Mean age was 60 years; 58% of
patients received extensive screening.
138 38 (39%) of 97
patients received extracranial radiotherapy and 24 (25%)
139 tween Jan 21, 2014, and March 18, 2016, 2691
patients received fixed triple (n=1078), tiotropium (n=1
140 Eight of 14
patients received further cycles in either 2- or 4-mo in
141 Eight
patients received ganciclovir treatment.
142 All
patients received gemcitabine 1000 mg/m(2) as a 30-min i
143 All
patients received general anesthesia.
144 All
patients received guideline-based usual care.
145 Patients received GVHD prophylaxis with tacrolimus and m
146 Sixty-seven (38%)
patients received HCT.
147 Three hundred three
patients received HDCT as second-line therapy with a 2-y
148 year PFS of 63% (95% CI, 57% to 68%), and 61
patients received HDCT as third-line or later therapy wi
149 The second
patient received hemodialysis.
150 Patients received hMSCs (100 million) by transendocardia
151 All
patients received IAIs in the presence of clinically rel
152 Patients received IB by metered-dose inhaler (40mug per
153 Most
patients received infliximab (n = 40 [87%]), with system
154 Patients received infusional avelumab monotherapy 10 mg/
155 c Ulcerative Colitis Activity Index (PUCAI),
patients received initial standardised treatment with me
156 Patients received intravenous 200 mg risankizumab, 600 m
157 Patients received intravenous nivolumab 0.1-10 mg/kg eve
158 Patients received intravenous pembrolizumab 2 mg/kg plus
159 Enrolled
patients received intravenous pembrolizumab 200 mg every
160 During each sequence,
patients received intravenous recombinant human C1 ester
161 15 HS
patients received IVIG (2 g/kg x2 doses)/rituximab (375
162 enrolled in hospice more often reported that
patients received "
just the right amount" of pain medici
163 Five percent of
patients received ketorolac.
164 Patients received LDV/SOF (90-400 mg) once daily for 12
165 The majority of
patients received LDV/SOF with or without ribavirin (91%
166 All
patients received ledipasvir-sofosbuvir once daily for 6
167 In older patients, low-education
patients received less intensive therapy (30% v 48%; adj
168 This
patient received levodopa and benserazide (200 and 50 mg
169 Eligible
patients received live zoster vaccine at investigators'
170 Fourteen of these twenty
patients received local treatment for symptomatic intest
171 atients were enrolled at our center, and 202
patients received Lotus and 335 ES3.
172 artment patients with septic shock, afebrile
patients received lower rates of emergency department an
173 Patients received luspatercept subcutaneously once every
174 mg per day, for 11 days; thereafter, all the
patients received maintenance therapy with itraconazole.
175 Thirteen
patients received MARS as a BTT, of which 9 were transpl
176 The majority of
patients received mechanical prophylaxis.
177 Patients received mechanical ventilation on 73% of the p
178 Because the majority of
patients received medical help later than 30 min after s
179 One hundred five
patients received mepolizumab (n = 54) or placebo (n = 5
180 Results Forty-seven
patients received MK-8242 across eight doses that ranged
181 Although black
patients received more intensive antihypertensive therap
182 ual care extracorporeal membrane oxygenation
patients received more opioids during the study period (
183 The
patients received multidisciplinary medical follow-up ex
184 uable for response to first-line therapy, 31
patients received neoadjuvant chemotherapy for localized
185 Thirty
patients received neoadjuvant treatment (NAT = 20%); 41
186 Between December 2001 and June 2015, 575
patients received neoadjuvant treatment and were schedul
187 Most extracorporeal membrane oxygenation
patients received neuromuscular blockade (46%) or were h
188 Consequently, the
patient received no specific treatment for his symptomat
189 However, one quarter of
patients received no treatment and lost vision.
190 For cycle 1,
patients received one of two treatment regimens.
191 696
patients received one or more doses of radium-223; 403 (
192 Overall, 56
patients received one preseasonal short-course booster A
193 onsecutively selected patient group (n = 91;
patients received one to 37 doses of gadoxetic acid) and
194 in a 1-year surveillance period during which
patients received ongoing HIV medical care.
195 Twenty-three
patients received only a single course of HDCT because o
196 In all, 936 (68.6%)
patients received only units of blood that had been stor
197 Patients received open-label MEDI2070 (210 mg) subcutane
198 Twenty-five
patients received open-label study drug.
199 erence largely determined which medication a
patient received (
OR = 3.13; p = 3 x 10(-37)).
200 Patients received oral dabrafenib 150 mg twice per day p
201 Patients received oral erlotinib 150 mg per day and intr
202 Patients received oral everolimus 10 mg/d until disease
203 Patients received oral fedratinib at a starting dose of
204 Patients received oral flecainide or placebo twice daily
205 Patients received oral ibrutinib 420 mg once daily until
206 Eligible
patients received oral venetoclax, starting at 20 mg per
207 ere enrolled; 94 patients received CE and 94
patients received PaCE.
208 A total of 84
patients received PCCs for the reversal of rivaroxaban o
209 Patients received pembrolizumab (10 mg/kg every 2 weeks)
210 Patients received pembrolizumab 200 mg every 3 weeks.
211 Patients received pembrolizumab at a dose of either 2 mg
212 As of June 20, 2016, 25
patients received pembrolizumab.
213 During the adaptation phase,
patients received performance-based feedback according t
214 Results Thirty-three
patients received perindopril, 31 received bisoprolol, a
215 (n = 49) and healthy controls (n = 39), and
patients received periodontal treatment.
216 Three
patients received peritransplantation treatment with min
217 y (age, 38.0+/-12.4 years; 74% male), and 48
patients received placebo (age, 40.6+/-11.4 years; 63% m
218 11.2] years; 178 were white [87.7%]), and 13
patients received placebo (mean [SD] age, 60.8 [12.2] ye
219 received benralizumab every 8 weeks, and 777
patients received placebo.
220 Three
patients received pomalidomide 2 mg/d with no dose-limit
221 All SC patients and 93% of LC
patients received preoperative planned radiotherapy.
222 stance use disorders) during months in which
patients received prescribed stimulant medication or ato
223 All
patients received prolonged-release tacrolimus, basilixi
224 using standardized patient instructors while
patients received question prompt lists and individualiz
225 Results Forty
patients received rAd-IFNalpha/Syn3 (1 x 10(11) vp/mL, n
226 Relatively fewer
patients received ranibizumab for initial neovascular AM
227 was primarily using beta-lactams, and 37% of
patients received rifampin.
228 nonrandomized multicenter trial, 45 eligible
patients received rituximab 375 mg/m(2) day 1 and bendam
229 All
patients received rituximab 375 mg/m(2) weekly for 4 wee
230 Forty-five (61%)
patients received second-line immunotherapy (cyclophosph
231 From July 2011 through October 2015, 38
patients received second-line nintedanib plus docetaxel.
232 Patients received selumetinib 100 mg orally per day plus
233 Seventeen
patients received short-course antibiotics (median durat
234 Patients received six cycles (every 3 weeks) of neoadjuv
235 Patients received six cycles of R-CHOP (rituximab [375 m
236 Fifty-two
patients received sofosbuvir 400 mg once daily and weigh
237 ed sofosbuvir plus ribavirin for 24 weeks, 4
patients received sofosbuvir plus daclatasvir for 12 wee
238 dian age, 59 y) treated with DAA therapy (21
patients received sofosbuvir plus ribavirin for 24 weeks
239 osbuvir plus daclatasvir for 12 weeks, and 2
patients received sofosbuvir plus simeprevir for 12 week
240 All
patients received sofosbuvir-velpatasvir once daily for
241 NET
patients received somatostatin radiopeptide therapy with
242 tal discharge, although approximately 50% of
patients received some opioid during their stay.
243 Thirty-five
patients received specific therapy against cryptosporidi
244 Patients received standard non-surgical periodontal trea
245 received high-flow nasal oxygen whereas 226
patients received standard oxygen.
246 To facilitate adherence,
patients received standardized HIV nurse/pharmacist supp
247 All
patients received subsequent local radiotherapy to the p
248 cessfully completed the program, and all 364
patients received successful operations.
249 A total of 54
patients received sunitinib.
250 In parts 1 and 2,
patients received supportive standard of care and initia
251 nophosphoryl lipid A (MPL((R)) ); 51 control
patients received symptomatic medication.
252 All
patients received systemic immunosuppression.
253 Approximately 24% of
patients received systemic IMs to manage select AEs, whi
254 Twenty
patients received systemic therapy for widely disseminat
255 Four thousand one hundred seventeen
patients received T2 MELD exceptions, of which 245 (6%)
256 Forty
patients received targeted treatment, in 22/40 (55%) cas
257 Results A total of 4,815
patients received TC (2,849 PP; 1,966 no PP); 2,292 pati
258 s received TC (2,849 PP; 1,966 no PP); 2,292
patients received TCH (1,444 PP; 848 no PP); and 1,638 p
259 Nearly all (97.6%)
patients received tenofovir disoproxil fumarate-containi
260 when only 1 type of platelet was available,
patients received that.
261 Patients received the Confusion Assessment Method for th
262 Five
patients received the decellularized lamina alone and 4
263 A total of 407
patients received the intended treatment and were availa
264 All
patients received the same chemotherapy regimen of borte
265 ulate P values for the log-rank tests.Twenty
patients received the taurolidine-citrate-heparin lock a
266 All
patients received the uniform prescription dose of 60 Gy
267 64% of
patients received their first medical help later than 30
268 sistant, HER2-positive MBC, but one third of
patients received therapy with T-DM1 for >/= 6 months, w
269 extracranial radiotherapy and 24 (25%) of 97
patients received thoracic radiotherapy.
270 eys from the same donor in such a way that 1
patient received Thymoglobulin induction and recipient o
271 Exposures: Before surgery,
patients received ticagrelor with or without aspirin or
272 All
patients received topical voriconazole, 1%, and after th
273 1146
patients received treatment (384 had tofacitinib monothe
274 umab (n=382) or placebo (n=189), of whom 569
patients received treatment (two patients in the tremeli
275 Three
patients received treatment activities of 5.1-7.5 GBq.
276 13
patients received treatment cycle 2; ten (77%) of the 13
277 Substantially fewer
patients received treatment specifically for hepatocellu
278 Patients received treatment until progression with carfi
279 Patients received treatment with ledipasvir-sofosbuvir,
280 d 7028 patients to treatment groups and 7020
patients received treatment.
281 y mantle cell lymphoma were enrolled and all
patients received treatment; median age 68 years.
282 Most surgical
patients received trimodal therapy with adjuvant CRT.
283 A total of 152
patients received tubes, and 148 patients did not.
284 Three hundred forty-one
patients received two consecutive courses of HDCT consis
285 All
patients received two cycles of ATO therapy during conso
286 Patients received two cycles of induction chemotherapy w
287 Patients received up to 16 sessions of the UP or an SDP
288 Patients received up to 4 cycles of combination treatmen
289 Patients received up to a total of 4 cycles of CPB treat
290 Patients received vadastuximab talirine IV on day 1 (5-6
291 Five cohorts (C1-C5) of 3
patients received variable molar doses of TF2 and approx
292 ncluding bortezomib in 22), whereas 8 and 13
patients received various immunosuppressive drugs or sym
293 Between June 12, 2012, and Jan 13, 2015, 32
patients received veliparib (22 in the dose-escalation g
294 d chemotherapy regimens were used: 377 (25%)
patients received vinorelbine, 343 (23%) received doceta
295 All
patients received volume-assist control mode until weani
296 All
patients received weekly subcutaneous injections, with t
297 Patients received whole-mouth ultrasonic debridement, sc
298 Eligible
patients received WTX101 monotherapy at a starting dose
299 2 [11.1] years; 173 were white [86.5%]), 203
patients received zoledronic acid every 12 weeks (mean [
300 A total of 416 women were randomized: 200
patients received zoledronic acid every 4 weeks (mean [S